Rocket Lab Corporation stock today: RKLB slides after insider sale filing as rally cools

Rocket Lab Corporation stock today: RKLB slides after insider sale filing as rally cools

New York, January 7, 2026, 11:05 EST — Regular session

  • Rocket Lab shares slipped in morning trade after an SEC filing disclosed an insider sale
  • The stock is hovering near a 52-week high after a sharp run-up
  • Traders are looking ahead to the next earnings update and further contract news

Rocket Lab Corp shares fell 1.8% on Wednesday after a filing showed its chief operations officer sold stock. RKLB was down $1.53 at $84.50 by 10:54 a.m. EST and had traded between $82.16 and $85.41. The stock has ranged from $14.71 to $86.25 over the past 52 weeks and gives Rocket Lab a market value of about $44.2 billion; analysts’ average 12-month target is $68.75 and the company has a trailing loss per share of about 39 cents, the data showed. Investing

The disclosure hit a stock that has been moving on momentum and defense headlines, with little patience for surprises. Insider selling is not rare, but it tends to draw more scrutiny when a company is still losing money and the share price is near its highs.

In a Form 4 signed on Jan. 6, chief operations officer Frank Klein reported selling 100,000 shares on Jan. 2 in multiple transactions at weighted-average prices between $67.6104 and $75.8002. The filing said the sales ran under a Rule 10b5-1 plan adopted on Sept. 19, 2025 — a pre-set trading plan that can execute automatically — and showed Klein still owned 1,169,487 shares after the transactions. SEC

Rocket Lab, which is based in Long Beach, California, has been drawing investor attention on U.S. national security work. The Space Development Agency said in December it awarded about $3.5 billion in agreements to four companies — Rocket Lab, Lockheed Martin, Northrop Grumman and L3Harris — to build 72 Tracking Layer satellites for launch in fiscal 2029. SDA Acting Director Gurpartap “GP” Sandhoo said the additional satellites would bring “near-continuous global coverage for missile warning and tracking.” Rocket Lab, in its own statement, put its award at $816 million including options and said, “Rocket Lab is honored to play a role in enabling this,” CEO Peter Beck said. SDA

But the shares are trading above most published target prices, and the stock’s speed cuts both ways. Any hint of schedule slippage on big government programs — or more insider selling — can quickly test sentiment in a name that has already priced in a lot of good news.

Rocket Lab has not confirmed the date for its next quarterly results, but its earnings release is estimated around Feb. 26, 2026, according to MarketBeat. Investors will be watching that update for margins, cash burn and any new detail on contract timing. Marketbeat

Stock Market Today

  • REGN crosses above average 12-month target; shares trade at $820
    January 8, 2026, 7:11 AM EST. Regeneron Pharmaceuticals (REGN) shares rose to $820.00, topping the consensus 12-month target of $816.30 set by analysts. When a target is reached, analysts typically reassess: downgrade on valuation or lift targets on improving fundamentals. The Zacks coverage universe spans 20 targets; the average hides a wide range, from a low $605.00 to a high $970.00, with a standard deviation of $87.334. The move highlights the wisdom of crowds in pricing, inviting investors to judge whether $816.30 represents ongoing upside or a stretched level. Ratings show Strong Buy or Buy signals outweighing Hold and Sell signals, with an average rating of 1.68 on a 1 (Strong Buy) to 5 (Strong Sell) scale. Source: Zacks via Quandl.
Google (Alphabet) GOOG stock rises as House tees up self-driving hearing; Waymo in focus
Previous Story

Google (Alphabet) GOOG stock rises as House tees up self-driving hearing; Waymo in focus

Intel stock jumps nearly 9% as CES Panther Lake push meets fresh Wall Street upgrade
Next Story

Intel stock jumps nearly 9% as CES Panther Lake push meets fresh Wall Street upgrade

Go toTop